Across TCGA pan-cancer cohorts, RNU6-462P RNA is linked to patient survival in 2 of 34 cancer types, making it the most broadly survival-associated RNU6-462P data layer.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RNU6-462P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6-462P expression acts as an unfavorable survival marker.
LIHC and LUSC are the cancer types where RNU6-462P RNA most reproducibly stratifies survival.